Fibrin Sealant in Surgery of Patients with a Hemorrhagic Diathesis

• References

• 1 Brown B, Steed DL, Webster MW, Makaroum MS, Spero JA, Bontempo FA, Ragni MV, Lewis JH. General surgery in adult hemophiliacs. Surgery 1986; 99: 154-159
• 2 Small M, Steven M, Freeman O, Lowe GD O, Belch JJ F, Forbes CD, Prentice CR M. Total knee arthroplasty in haemophilic arthritis. J Bone Joint Surg 1983; 65 B 163-165
• 3 Spivack AR, Avioli LV. Orthopedic and medical treatment of patients with hemophilia. Arch Intern Med 1983; 143: 1431-1433
• 4 Iwata H, Oishi Y, Itoh A, Ishiguro N, Yamaga H, Miyamoto N, Kamiya T. Surgical excision of hemophilic pseudotumor of ilium. Clin Orth Rel Res 1992; 284: 234-238
• 5 Sindet-Pedersen S. Hemostasis in oral surgery - the possible pathogenic implications of oral fibrinolysis on bleeding. Dan Med Bull 1991; 38: 427-442
• 6 Thomas DP, Lee CA, Colvin BT, Dasani H, Dolan G, Giangrande PL E, Jones P, Lucas G, Cantwell O, Harman CT. Clinical experience with a highly purified factor IX concentrate in patients undergoing surgical operations. Haemophilia 1995; 1: 17-32
• 7 Blatt PM, White CG, McMillan CW, Webster WP. Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody. J Am Med Assoc 1984; 251: 67
• 8 Parry DH, Bloom AL. Failure of factor VIII inhibitor by passing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies. J Clin Pathol 1978; 31: 1102-1105
• 9 Stenbjerg S, Jorgensen J. Resistance to activated FIX concentrate (FEIBA). Scand J Haematol 1977; 18: 421-426
• 10 Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CR M. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. Semin Hematol 1993; 30 Suppl (Suppl. 01) 10-21
• 11 Sjamsoedin EJ, Heijmen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Asten P, Sixma JJ. The effect of activated prothrombin-complex concentra-te (Feiba) on joint and muscle bleed in patients with hemophilia A and antibodies to factor VIII. N Engl J Med 1981; 305: 717-721
• 12 Kasper CK. Thromboembolic complications. Thromb Diath Haemorrh 1975; 33: 640-644
• 13 Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factorXIII-deficient plasma with the purified zymogen. J Clin Invest 1983; 71 (05) 1336-1341
• 14 Glander JA, Nossal R. Effects of crosslinking on the rigidity and proteolytic susceptibility of human fibrin clots. Thromb Res 1983; 30 (03) 273-288
• 15 Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp PE, Teller DC. Three dimensional structure of a transglutaminase :human blood coagulation factor XIII. Proc Natl Acad Sci USA 1994; 91: 7296-7300
• 16 Tamaki T, Aoki N. Crosslinking of a₂-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-14772
• 17 Aoki N, Tamaki T, Sakata Y, Ichinose A. Crosslinking of a₂-plasmin inhibitor to fibrin, its comparison with fibronectin and its physiological significance. In: Egbring R, Klingemann HG. Eds. Factor XIII and fibronectin. Die Marburg:Medizinische Verlagsgesllschaft 1982: 205-212
• 18 Homyak TJ, Shafer JA. Interaction of factor XIII with fibrin as substrate and cofactor. Biochemistry 1992; 31: 423-429
• 19 Morten sen SB, Sottrup-Jensen L, Hansen HF, Rider D, Petersen TE, Magnusson S. Sequence location of a putative transglutaminase crosslinking site in human a₂ macroglobulin. FEBS 1981; 129: 314-317 (lett)
• 20 Jensen PH, Lorand L, Ebbesen P, Gliemann J. Type-2-plasminogen activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa:transglutaminase-catalyzed crosslinking to cellular and extracellular structures. Eur J Biochem 1993; 214: 141-146
• 21 Aeschlimann D, Paulsson M. Transglutaminases-.protein cross-linking enzymes in tissues and body fluids. Thromb Haemost 1994; 71: 402-415 (review)
• 22 Hansen MS. Fibronectin and coagulation factor XIII increases blood platelet adhesion to fibrin. Thromb Res 1984; 34 (06) 551-556
• 23 Fésus L, Metsis ML, Muszbek L, Koieliansky VE. Transglutaminase- sensitive glutamine residues of human plasma fibronectin, revealed by studying its proteolytic fragments. Eur J Biochem 1986; 154: 371-374
• 24 Bale MD, Mosher DF. Effects of thrombospondin on fibrin polymerization and structure. J Biol Chem 1986; 261 (02) 862-868
• 25 Bale MD, Mosher DF. Thrombospondin is a substrate for blood coagulation factor Xllla. Biochemistry 1986; 25 (19) 5667-5673
• 26 Sane DC, Moser TL, Pippen AM, Parker CJ, Achyuthan KE, Greenberg CS. Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun 1988; 157 (01) 115-120
• 27 Hada M, Kaminski M, Bockenstedt P, McDonagh J. Covalent crosslinking of von Willebrand factor to fibrin. Blood 1986; 68 (01) 95-101
• 28 Mosher DF. Cross-linking of fibronectin to collagenous proteins. Mol Cell Biochem 1984; 58: 63-68
• 29 Ishikawa-Sakurai M, Hayashi M. Two collagen-binding domains of vitronectin. Cell Struct Funct 1993; 18 (04) 253-259
• 30 Bockenstedt P, McDonagh J. andin RL Binding and covalent cross- linking of purified von willebrand factor to native monomeric collagen. J Clin Invest 1986; 78 (02) 551-556
• 31 Barry EL, Mosher DF. Factor Xllla-mediated cross-linking of fibronectin in fibroblast cell layers. Cross-linking of cellular and plasma fibronectin and of amino-terminal fibronectin fragments. J Biol Chem 1989; 264 (07) 4179-4185
• 32 De Palma L, Chriss VR, Luban NL C. The preparation of fibrinogen concentrate for use as fibrin glue by four different methods. Transfusion 1993; 33: 717-720
• 33 Salz R, Dimick A, Harris C, Grotting JC, Psillakis J, Vasconez LO. Application of autologous fibrin glue in bum wounds. J Bum Care Rehabil 1989; 10: 504-507
• 34 Casali B, Rodeghiero F, Tosetto A, Palmieri B, Immovilli R, Ghedini C, Rivasi P. Fibrin glue from single donation autologous plasmapheresis. Transfusion 1992; 32: 641-643
• 35 Hartman AR, Galanakis DK, Honig MP, Seifert FC, Anagnostopoulus CA. Autologous whole plasma fibrin glue. Arch Surg 1992; 127: 357-359
• 36 Oz MC, Jeevanandam V, Smith CR, Williams MR, Kaynar AM, Frank RA, Mosca R, Reiss RF, Rose EA. Autologous fibrin glue from intraoperatively collected platelet-rich plasma. Ann Thorac Surg 1992; 53: 530-531
• 37 Hilfenhaus J, Weidmann E. Fibrin glue safety :inactivation of potential viral contaminants by pasteurization of the human plasma components. Drug Res 1985; 35: 1617-1619
• 38 Cuthbertson B, Reid KG, Foster PR. Viral contamination of human plasma products and procedures for preventing vims transmission by plasma products. In: Blood separation and plasma fractionation. Wiley-Liss 1991; 385-435
• 39 Bumouf-Radosevich M, Bumouf T, Huart JJ. Biochemical and physical properties of solvent detergent treated fibrin glue. Vox Sang 1990; 58: 77-84
• 40 Communications at:Fibrin sealantxharacterization and clinical uses.. USUHS; Bethesda,Maryland: 1994
• 41 Rapaport SI, Zivelin A, Monow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992; 97: 84-91
• 42 Stocker KF. Snake venom proteins affecting hemostasis and fibrinolysis. In: Medical use of snake venom proteins. Stocker KF. ed. Boca Raton, Boston; CRC Press: 1990: 136-140
• 43 Fibrin sealant:Characteristics and clinical uses, Uniform Services University of the Health Sciences. Bethesda; Maryland: 8-9 12/1994
• 44 Martinowitz U, Ozer Y, Varon D, Engel Y, Yaffe B. Fibrin sealing in nerve repair. Thromb Haemostas 1993; 69: 1287 (abstract)
• 45 Gehringer W, Stadler M, Josic Dj, Biesert L, Nur I, Schwinn H. Octacoha double vims inactivated biological adhesive, derived from human plasma. Thromb Haemostas. 1995 submitted (abstract)
• 46 Hoots K, McLeod J, Eggers E, Berg J, Lee M, Gomperts E. Pilot study to evaluate efficacy of fibrin sealant (human) on hemostasis in hemophiliacs undergoing tooth extractions. Blood 1993; Suppl 82a 598 (abstract)
• 47 Martinowitz U, Mazar AL, Rakocz M, Varon D, Gitel SN, Ramot B. aicher. Dental extraction for patients on oral anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1990; 70: 274-277
• 48 Rakocz M, Mazar A, Varon D, Spierer S, Martinowitz U. Dental extractions in patients with bleeding disorders, the use of fibrin glue. Oral Surg Oral Med Oral Pathol 1993; 75: 280-282
• 49 Martinowitz U, Varon D, Yonash P, Bar-Maor A, Brenner B, Leibovitch I, Heim M. Circumcision in hemophilia:the use of fibrin glue for local hemostasis. J Urol 1992; 148: 855-857
• 50 Martinowitz U, Schulman S, Gitel S, Horoszowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Brit J Haematol 1992; 82: 729-734
• 51 Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemostas 1994; 72: 403-407
• 52 Schulman S, Gitel SN, Zivelin A, Mandalaki T, Katsarou O, Varon D, Martinowitz U. The feasibility of using factor IX concentrates for continuous infusion. Haemophilia. 1995 1. in press
• 53 Martinowitz U, Schulman S. Continuous infusion of coagulation products. Int J Ped Hematol Oncol. 1994 1. (in press.)
• 54 Wepner F, Fries R, Platz H. The use of the fibrin adhesion system for local hemostasis in oral surgery. J Oral Maxillofac Surg 1982; 40: 555-558
• 55 Grimm G, Niekisch R. Complications in hemophilic patients under conditions of fibrin sealing. In: Fibrin sealant in operative medicine. Plastic surgery, maxillofacial and dental surgery. Schlag G, Redl H. eds. Springer Verlag, Berlin Heidelberg; 1986. 4 178-182
• 56 Baudo F, deCataldo F, Landonio G, Muti G. Management of oral bleeding in haemophilic patients. Lancet 1988; 2: 1082 (letter)
• 57 Carmona FG, Monleon V. Tooth extraction, coagulation disorders and fibrin sealant:results after ten years of experience. Update and Future trends in fibrin sealing in surgical and non-surgical fields, Vienna: 1992: 162 (abstract)
• 58 Neukam FW, Reich R, Bartels M, Steinke M, Adam S. Dentoalvelar surgery and tooth extractions in patients with hemophilia A, hemophilia B and v. Willebrand-Jurgens-syndrome. Update and Future trends in fibrin sealing in surgical and non-surgical fields Vienna: 1992: 163 (abstract)
• 59 Bagenholm T, Stigendal L, Tengbom L. Tissucol/fibrin sealant for oral surgery in patients with coagulation disorders. XXI Int Congr of the WFH Mexico City: 1994: 37 (abstract)
• 60 Ginelli G, Bucciarelli P, Misani M, Carpenedo M, Pignanelli M, Moia M. Fibrin glue plus tranexamic acid mouthwashing in patients on oral anticoagulants undergoing dental extractions:a randomized study. XV Congr of the ISTH Jerusalem: 1995. submitted (abstract)
• 61 Femandez-Palazzi F, Rivas S. The use of “fibrin seal” in surgery of coagulation diseases with special reference to cysts and pseudotumors. In: Dohring S, Schulitz KP. eds. Orthopedic problems in hemophilia.. W. Zuckschwerdt Verlag Miinchen-Bem-Wien; 1985. pp 170-179
• 62 Kluft C, Verheijen JH, Jie AFH J, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO. The postoperative fibrinolytic shut down.a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-610
• 63 Juhan-Vague I, Aillaud MF, Alessi MC. Biological variations in t-PA activity and antigen. in: Kluft C. Tissue type plasminogen activator (t- PA):physiological and clinical aspects. Boca Raton; CRC Press: 1988. 2 69-87
• 64 Gibble JW, Ness PM. Fibrin glue:the perfect operative sealant. Transfusion 1990; 30: 741-747
• 65 Martinowitz U, Schulman S, Solomon AS. Resistance of fibrin sealants to proteolysis in a guinea pig eye model. Submitted for publication
• 66 Pipan CM, Glasheen WP, Matthew TL, Gonias SL, Hwang L-J, Jane JA, Spotnitz WD. Effects of antifibrinolytic agents on the life span of fibrin sealant. J Surg Res 1992; 53: 402-407
• 67 Shurafa M, Macintosh RB. Management of dental extraction in two hemophilia A patients with F VIII inhibitor. J Oral Maxillofac Surg 1987; 45: 698-701
• 68 Rickards KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995; 1 (suppl.) 8-13
• 69 van den Ham AC, Kort WJ, Weijma IM, van den Ingh HF G M, Jeekel H. Effect of antibiotics in fibrin sealant CHI healing colonic anastomoses in the rat. Brit J Surg 1992; 79: 525-528
• 70 Hashimoto J, Kurosaka M, Yoshiya S, Hirohata K. Meniscal repair using fibrin sealant and endothelial growth factor. Am J Sports Med 1992; 20: 537-541
• 71 Kurianski J, Martinowitz U, Bass A, Gitel SN, Adar E, Mor A, Ayalon A, Keller N. Antibiotic incorporation into fibrin glue:antibacterial properties and dose related inhibitory effect on clot formation. Submitted for publication
• 72 McAlister V, O’Dwyer PS, O’Higgins NJ. Effect of fibrin sealant on the healing colonic anastomosis. Brit J Surg 1991; 78: 889 (letter)
• 73 Byme DJ, Hardy J, Wood RA B, Macintosh R, Hopwood D, Cuschieri A. Adverse influence of fibrin sealant on the healing of high risk sutured colonic anastomoses. J R Coll Surg Edinb 1992; 37: 394-398
• 74 de Virgilio C, Dubrow T, Sheppard BB, MacDonald WD, Nelson RJ, Lesavoy MA, Robertson JM. Fibrin glue inhibits intra-abdominal adhesion formation. Arch Surg 1990; 125: 1378-1381
• 75 Sheppard BB, de Virgilio C, Bleiweis M, Milliken JC, Robertson JM. Inhibition of intra-abdominal adhesion formation. Am Surg 1993; 59: 786-790
• 76 van den Ham AC, Kort WJ, Weijmo IM, van den Ingh HF G M, Jeekel H. Effect of fibrin sealant on the integrity of colonic anastomoses in rats with faecal peritonitis. Eur J Surg 1993; 159: 425-432
• 77 Chang H, Wu GJ, Pemg WL, Hwang FY, Hung CR. Effects of fibrin glue on hemostasis. J Formosan Med Assoc 1992; 91: 601-607
• 78 Banninger H, Hardegger T, Tolber A, Barth A, Schiipbach P, Reinhart W, Lammle B, Furlan M. Fibrin glue in surgery:frequent development of inhibitors of bovine thrombin and human factor. Brit J Haematol 1993; 85: 525-532
• 79 Maier WA. Fibrin sealant in circumcision. Presentation at:Update and Future Trends in fibrin Sealing in Surgical and Non-Surgical Fields. Vienna, Austria: 1992
• 80 Sindet-Pedersen S, Ramsrom G, Bemvil S, Blomback M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant treated patients undergoing oral surgery. N Engl J Med 1989; 320: 840-843
• 81 Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe F XI deficiency without plasma replacement. Blood Coag Fibrinol 1992; 91: 601-607